| (19) |
 |
|
(11) |
EP 4 397 682 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
21.08.2024 Bulletin 2024/34 |
| (43) |
Date of publication A2: |
|
10.07.2024 Bulletin 2024/28 |
| (22) |
Date of filing: 29.05.2018 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (30) |
Priority: |
31.05.2017 GB 201708655
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
18743683.7 / 3630946 |
| (71) |
Applicant: UCB Biopharma SRL |
|
1070 Brussels (BE) |
|
| (72) |
Inventors: |
|
- BEN YAHIA, Bassem
1070 Brussels (BE)
- MALPHETTES, Laetitia
1070 Brussels (BE)
- KOCHANOWSKI, Nadine
1070 Brussels (BE)
- RENNER, Gill
Slough, SL1 3WE (GB)
- DURRAN, Sandrine
Slough, SL1 3WE (GB)
- YATES, Andrew Jeffrey
Slough, SL1 3WE (GB)
|
| (74) |
Representative: UCB Intellectual Property |
|
c/o UCB Celltech
IP Department
208 Bath Road
Slough, Berkshire SL1 3WE
Slough, Berkshire SL1 3WE (GB) |
|
| |
|
| (54) |
CELL CULTURE METHODS |
(57) The present invention relates to the use of limited amounts of cysteine and tryptophan
in the cell culture medium during production of recombinant proteins, and in particular
antibodies. Proteins and antibodies produced under such controlled conditions exhibit
reduced heterogeneity, in particular reduced charge variants heterogeneity.